Identification of the N-Linked Glycosylation Sites on the High Density Lipoprotein (HDL) Receptor SR-BI and Assessment of Their Effects on HDL Binding and Selective Lipid Uptake*

Marisa ViñalsDagger, Shangzhe Xu, Eliza Vasile, and Monty Krieger§

From the Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Received for publication, October 29, 2002, and in revised form, November 8, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The murine class B, type I scavenger receptor mSR-BI, a high density lipoprotein (HDL) receptor that mediates selective uptake of HDL lipids, contains 11 potential N-linked glycosylation sites and unknown numbers of both endoglycosidase H-sensitive and -resistant oligosaccharides. We have examined the consequences of mutating each of these sites (Asn right-arrow Gln or Thr right-arrow Ala) on post-translational processing of mSR-BI, cell surface expression, and HDL binding and lipid transport activities. All 11 sites were glycosylated; however, disruption of only two (Asn-108 and Asn-173) substantially altered expression and function. There was very little detectable post-translational processing of these two mutants to endoglycosidase H resistance and very low cell surface expression, suggesting that oligosaccharide modification at these sites apparently plays an important role in endoplasmic reticulum folding and/or intracellular transport. Strikingly, although the low levels of the 108 and 173 mutants that were expressed on the cell surface exhibited a marked reduction in their ability to transfer lipids from HDL to cells, they nevertheless bound nearly normal amounts of HDL. Indeed, the affinity of 125I-HDL binding to the 173 mutant was similar to that of the wild-type receptor. Thus, N-linked glycosylation can influence both the intracellular transport and lipid-transporter activity of SR-BI. The ability to uncouple the HDL binding and lipid transport activities of mSR-BI by in vitro mutagenesis should provide a powerful tool for further analysis of the mechanism of SR-BI-mediated selective lipid uptake.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Scavenger receptor class B, type I, SR-BI,1 is a 509-residue, ~82-kDa integral membrane cell surface glycoprotein of the CD36 superfamily that was the first high density lipoprotein (HDL) receptor to be characterized in detail (1, 2). SR-BI helps control the structure and metabolism of HDL by mediating the transport of lipids from HDL to cells. The mechanism by which SR-BI mediates this lipid transport differs from the classic LDL receptor pathway of endocytosis, in which the entire lipoprotein is internalized via coated pits and subsequently hydrolyzed by lysosomal enzymes (3). Instead, HDL binds to SR-BI, lipids of HDL (primarily neutral lipids such as cholesteryl esters in the core of the particle) are transported into the cells, and the lipid-depleted particle is released into the extracellular space (1, 2, 4, 5). This mechanism is called selective lipid uptake (2, 4, 5). Numerous studies indicate that SR-BI-mediated selective lipid uptake is a two-step process involving productive binding of HDL (1, 6, 7) followed by binding-dependent lipid transfer. In addition to mediating selective lipid uptake, SR-BI can mediate cholesterol efflux from cells to HDL (8) via a binding-dependent process (6, 7, 9) (however see Ref. 10 for alternative view). The physiologic significance of SR-BI-mediated cholesterol efflux is not clear. In addition to HDL, SR-BI can bind tightly to numerous other ligands, including native and modified LDL (reviewed in Ref. 2).

In vivo analyses of the function of SR-BI, primarily using SR-BI homozygous null mice (11, 12) and murine hepatic overexpression of SR-BI transgenes (13-18), have shown that SR-BI can profoundly influence several physiologic systems (also see Ref. 46). For example, adenovirus-mediated hepatic overexpression of SR-BI increases biliary cholesterol concentration, whereas complete loss of expression lowers biliary cholesterol (12, 13, 19). Female SR-BI knock-out mice are infertile due to lipoprotein-dependent defects in oocyte development (12, 20). Loss of SR-BI expression can disrupt red blood cell development (21) and influence the development of atherosclerosis (SR-BI expression is protective (12, 14, 16, 18)), coronary heart disease, and premature death (23).

The molecular mechanisms underlying SR-BI activity and the relationship of the structure of SR-BI to its functions are not well-understood. To better understand the structure of SR-BI and its mechanism of action, we have conducted several studies involving the generation and characterization of SR-BI mutants (6, 9, 25). Some of these studies have shown that the large, extracellular loop of SR-BI, which is glycosylated, plays a critical role in mediating not only ligand binding but also the selective lipid uptake step (6, also see Ref. 26). To date, the functional role of the extensive N-linked glycosylation of SR-BI has not been explored. Oligosaccharides in glycoproteins can serve a variety of functions, including facilitating protein folding, protecting against proteolysis, directly participating in intermolecular interactions, directing intracellular trafficking and secretion, and influencing cell surface expression and activity (27-29). In some cases it has not been possible to attribute a specific function to a given N-linked glycan.

Here we report the effects of mutating (Asn right-arrow Gln or Thr right-arrow Ala) each of the 11 potential N-linked glycosylation sites (Asn-X-Ser/Thr) in the extracellular loop of murine SR-BI on the extent of glycosylation (changes in apparent mass), cell surface expression, 125I-HDL binding, and cellular uptake of lipid from HDL. The results show that all 11 sites are glycosylated and that two of these sites at positions 108 and 173 are essential for normal surface expression and efficient lipid uptake but not HDL binding. Indeed, the position 173 mutation inhibits most SR-BI-mediated lipid uptake without significantly altering the apparent binding affinity of HDL or maximal amount of binding. They also show that the HDL binding and lipid transport activities of mSR-BI can be uncoupled.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [1alpha ,2alpha (n)-3H]Cholesteryl oleoyl ether ([3H]CEt, 1 mCi/ml, specific activity of 58 Ci/mmol) was from Amersham Biosciences. Human HDL, 125I-HDL, DiI-labeled HDL, Alexa-labeled HDL, and [3H]CEt-HDL were prepared as described previously (1, 6, 9, 25). The GenePORTER transfection reagent was from GTS Inc. Rabbit antiserum against the extracellular domain of mSR-BI was previously described (anti-mSR-BI KKB-1 antiserum, 1:1000 dilution), a generous gift from K. Kozarsky (9), FITC-conjugated goat anti-rabbit IgG (1:1000 dilution, Cappel, West Chester, PA). All other reagents were obtained from standard commercial sources or as described previously (30). All of the expression vectors for mSR-BI and mutants were constructed in pCDNA1 (Invitrogen) using standard recombinant DNA techniques. Wild-type mSR-BI expression vectors used for these studies included pmSR-BI 77 (1) and a minor variant ex68, which contained small differences in the linker region to facilitate cloning and restriction digestion (25).

Site-directed Mutagenesis of mSR-BI-- Site-directed mutagenesis to create the mutants was performed on SR-BI cDNA in the pCDNA1 vector using a commercial kit (QuikChangeTM site-directed mutagenesis kit, Stratagene Inc., La Jolla, CA) according to the manufacturer's instruction. Briefly, a pair of complementary primers with 25-35 bases was designed for each mutagenesis, and the mutation to change asparagine to glutamine or threonine to alanine was placed in the middle of the primers. The wild-type mSR-BI cDNA within pcDNA was amplified for 16 cycles in a DNA thermal cycler using Pfu DNA polymerase with these primers. After digestion of the template DNA with DpnI, the amplified mutant DNA was transformed into Escherichia coli (MC1061/P3 strain (Invitrogen)). The mutations were confirmed by automated DNA sequencing. The sequences of the mutagenic primers for the Asn right-arrow Gln mutants were: 102, 5'-TTC AGA CAA AAG GTC CAG ATC ACC TTC AAT GAC-3'; 108, 5'-ATC ACC TTC AAT GAC CAG GAC ACC GTG TCC TTC-3'; 116, 5'-C GTG TCC TTC GTG GAG CAG CGC AGC CTC CAT TTC C-3'; 173, 5'-C CAG CGT GCT TTT ATG CAG CGC ACA GTT GGT GAG-3'; 212, 5'-CTG TTT GTT GGG ATG CAG AAC TCG AAT TCT GGG-3'; 227, 5'-TTC ACG GGC GTC CAG CAA TTC AGC AGG ATC CAT C-3'; 255, 5'-CTGCCCGGAGGTACCTTGGATCATGTTACACTGCTC-3'; 288, 5'-CC ATG AAG CTG ACC TAC CAG GAA TCA AGG GTG TTT G-3'; 310, 5'-GAT ACT CTG TTT GCC CAG GGG TCC GTC TAC CCA-3'; 330, 5'-ACCTGCAGGTGCTGACTTGCTGAATGCCAGACTC-3'; 383, 5'-C ACT GGG ATC CCC ATG CAG TGT TCT GTG AAG ATG C-3'. The sequences of the mutagenic primers for the Thr right-arrow Ala mutants were, 108 (T right-arrow A), 5'-C AAT GAC AAC GAC GCC GTG TCC TTC G-3'; 173 (T right-arrow A), 5'-GCT TTT ATG AAC CGT GCA GTT GGT GAG ATC-3'.

Cell Culture and Transfection-- COS M6 cells were grown in Dulbecco's modified Eagle's medium with 50 units/ml penicillin, 50 µg/ml streptomycin, and 2 mM glutamine (medium A) supplemented with 10% fetal bovine serum (medium B) at 37 °C in a humidified 5% CO2/95% air incubator. For transfections, 1.5 × 105 cells/well of COS M6 cells were plated on day 0 in 24-well dishes in medium B. On day 1, cells were transfected with the plasmid expression vectors for wild-type or mutant mSR-BI, or with a control plasmid that did not encode a protein product (pCDNA1), using the DEAE-dextran method described previously (31). On day 2, the medium was replaced with medium B containing 1 mM sodium n-butyrate (medium C). On day 3, transfected cells were used for flow cytometry, 125I-HDL binding assays, or immunoblotting.

Flow Cytometry-- Cells were labeled with either DiI-HDL alone (assay of lipid uptake activity), with anti-mSR-BI KKB-1 antiserum followed by FITC-conjugated goat anti-rabbit IgG alone, or both, or with Alexa-HDL alone (assay of HDL binding) or both Alexa-HDL and DiI-HDL. We used flow cytometry to quantitate the uptake of DiI from DiI-HDL and the binding of Alexa-HDL. On day 3 cells were washed once with medium A and then incubated either at 37 °C for 2 h with the indicated concentration of DiI-HDL in medium A containing 0.5% (w/v) fatty acid-free BSA (medium D) or at 4 °C for 1 h in Ca2+- and Mg2+-free PBS (fPBS) containing 0.5% (w/v) fatty acid-free BSA (buffer A), 2 mM EDTA, and 10 µg of protein/ml Alexa HDL. The DiI-HDL-treated cells were then washed twice with fPBS, suspended by gentle pipetting in buffer A, and analyzed using a FACScan (BD Biosciences) flow cytometer as previously described (6, 9, 25). The Alexa-HDL-treated cells were detached from the plate by gently pipetting and held on ice. Immediately prior to flow cytometric analysis, the cells were pelleted at 500 × g for 2 min and resuspended in buffer A.

The levels of cell surface expression of SR-BI were determined by flow cytometry using the SR-BI-specific antibody KKB-1 (9). On day 3, cells were washed once with medium A and then incubated at 4 °C for 1 h in PBS containing 0.5% fatty acid-free BSA (buffer B) and KKB-1 antiserum (1:1000 dilution). The cells were then washed twice with PBS and incubated for 40 min at 4 °C in 200 µl of buffer B containing FITC-conjugated goat anti-rabbit IgG (1:1000 dilution, Cappel, West Chester, PA). After two additional washes with fPBS, the cells were suspended by gentle pipetting in buffer A.

For two-color flow cytometry, cells were first labeled with DiI-HDL at 37 °C as described above, washed twice with PBS, and then incubated with either Alexa-HDL or anti-mSR-BI KKB-1 antiserum and FITC-conjugated goat anti-rabbit IgG as described above. The mean values of the fluorescence intensity are reported. Receptor-specific values for DiI uptake, Alexa-HDL binding, and surface expression are defined as the differences between the values determined using cells transfected with the plasmids encoding the wild-type or mutant receptors and those determined using cells transfected with the non-coding (empty vector) controls. The receptor-specific values for the mutant receptors are usually expressed as the percentage of those determined using the wild-type receptor. In some cases, the values were normalized by dividing by the relative levels of surface expression determined using the KKB-1 antibody.

The ratios of 125I-HDL binding to Alexa-HDL and KKB-1 binding were similar for all cells expressing either wild-type mSR-BI or the glycosylation mutants. It is possible, but unlikely, that any given mutation simultaneously and equally changed both HDL binding and KKB-1 binding. It therefore seems unlikely that any of the mutations altered the ability of KKB-1 to bind to the receptor. Thus, quantitative analysis of KKB-1 binding to intact cells was used as a measure of receptor surface expression for both wild-type and mutant receptors.

Generation of Stably Transfected ldlA-7 Cells Expressing mSR-BI Containing an N173Q Mutation-- Stable transfectants were generated using the LDL receptor-deficient CHO cell line ldlA-7 (32) as previously described (1). Cells grown in 100-mm dishes were cotransfected with 10 µg of pcDNA1 encoding mSR-BI containing a N173Q mutation and 1 µg of pBK-CMV plasmid (Stratagene) using the GenePORTER transfection reagent according to the manufacturer's instructions. Stably transfected cells were selected in Ham's F-12 medium containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 2 mM glutamine (medium E) supplemented with 5% fetal bovine serum (medium F) and 500 µg/ml G418 for 2 weeks as previously described (9). Surface expression of the mutant mSR-BI was detected using the KKB-1 antibody as described above using flow cytometry, and individual cells with high levels of expression were sorted, isolated, and cloned as described previously (25), and one clone designated ldlA[N173Q] was used for the experiments shown.

125I-HDL Binding Assay-- The binding of 125I-HDL to ldlA-7, ldlA[mSR-BI], and ldlA[N173Q] cells was measured in 24-well plates as previously described (1). A similar assay was used to measure binding to transiently transfected COS cells with the following minor modifications: On day 3 transfected cells were washed once with medium A and then incubated with the indicated concentrations of 125I-HDL in medium D. Receptor-specific binding values for transfected COS cells were defined as the differences between values for the receptor-expressing cells and control cells transfected with the empty vector.

Cellular Uptake of [3H]CEt from [3H]CEt-HDL-- Cellular uptake of [3H]CEt from [3H]CE-HDL was measured after a 2-h incubation at 37 °C as previously described (1). Receptor-specific uptake was calculated as the difference in the values obtained in the presence (single incubations, nonspecific) and absence (duplicate incubations, total) of a 40-fold excess unlabeled HDL.

Preparation of Cell Lysates and Treatment with Endoglycosidase H-- Cells were grown in medium B and lysed with detergent (50 mM Tris, 1 mM EDTA, 0.1% Triton), and aliquots (20-40 µg of protein) were denatured in 5% SDS, 10% beta -mercaptoethanol buffer at 100 °C for 10 min. Then, 1/10 volume of 10× G5 buffer (0.5 M sodium citrate (pH 5.5 at 25 °C)) and 2-10 units of endoglycosidase H (endo H) were added, and the mixture was incubated at 37 °C overnight. Undigested controls were incubated without the added enzyme.

Immunoblotting-- Cell lysates were analyzed by immunoblotting with the rabbit anti-SR-BI anti-peptide polyclonal antibody 495 (1, 11), and the blots were visualized with the ECL chemiluminescent detection system (Amersham Biosciences) and x-ray film as previously described (33).

Immunofluorescence-- On day 2 after plating, cells were fixed with 4% formaldehyde in PBS for 30 min at room temperature, washed twice with PBS, incubated for 15 min with 50 mM NH4Cl, blocked for 1 h with 10% fetal bovine serum in PBS, incubated overnight at 4 °C with KKB-1 antibody (1:1000 dilution), and then incubated with Texas Red-conjugated anti-rabbit secondary antibody (1:500 dilution) at room temperature for 1 h in the dark. Controls included rabbit IgG (10 µg/ml) as primary antibody followed by secondary antibody or omitting the primary antibody and incubating only with secondary antibody. Samples were then washed with PBS three times for 5 min and mounted in Vectashield (Vector Laboratories, Burlingame, CA). The cells were viewed with a Zeiss Axioplan microscope (×63 and 1.3 numerical aperture objective) and a confocal laser scanning system (1024 Bio-Rad MRC equipped with an argon krypton laser). Images were saved as tiff format files and edited with Photoshop 6.0 software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of N-Linked Glycosylation Sites on mSR-BI by Mutagenesis-- Murine SR-BI contains 11 potential N-linked glycosylation sites (Asn-X-Ser/Thr) in its extracellular domain (1); these include the asparagines at positions: 102, 108, 116, 173, 212, 227, 255, 288, 310, 330, and 383. These sites are conserved in the mouse and rat and, with the exception of positions 116 and 288, in the human and hamster. Previous studies have shown that, when expressed in CHO cells, at least five of these sites in mSR-BI are modified by glycosylation and that N-glycosylation appears to account for most of the difference between the predicted (~57 kDa, based on amino acid sequence) and observed (~82 kDa determined by SDS-PAGE) masses of SR-BI (33). The observed apparent mass of SR-BI is ~82 kDa in a variety of both cultured cells and tissues, suggesting that the extent of N-glycosylation is similar in these cells and tissues. To determine which of the potential N-linked sites were glycosylated, we (a) generated a collection of 11 mutant mSR-BI cDNA expression vectors in which one of each of the 11 sites was mutated (Asn right-arrow Gln), (b) expressed the wild-type and mutant proteins in COS M6 cells by transient transfection, and (c) compared their electrophoretic mobilities by SDS-PAGE and immunoblotting with an anti-C terminus antipeptide antibody (1). This antibody can recognize mSR-BI independently of its glycosylation state (Ref. 33 and data not shown). The expectation was that there would be a small increase in electrophoretic mobility (reduced apparent mass) in a mutant mSR-BI relative to the wild-type if the mutated site were glycosylated in the wild-type protein. Fig. 1A shows that each of the 11 mutants (lanes 1-4, 6-9, 11, 13, and 14) exhibited a slightly greater mobility than the wild-type receptor (lanes 5, 10, and 12). Thus, we conclude that all 11 potential N-glycosylation sites are normally glycosylated in COS cells and probably in many other mammalian cells in culture and in vivo.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 1.   Immunoblot analysis of wild-type mSR-BI (None) and its single N-glycosylation site mutants: electrophoretic mobility shifts and endoglycosidase H sensitivity. COS cells were transiently transfected with expression vectors encoding either wild-type mSR-BI (None) or mSR-BI in which a single amino acid mutation in the codon for Asn at each of the 11 potential N-linked glycosylation sites (indicated by the number of its location in the sequence) was mutated to that for Gln. Cell lysates (40 µg of protein) were analyzed by SDS-10% polyacrylamide gel electrophoresis and immunoblotting with an anti-mSR-BI C-terminal anti-peptide antibody (anti-mSR-BI495) without enzymatic treatment (A) or were incubated overnight at 37 °C with 0.1 unit/ml of endo H prior to electrophoresis and immunoblotting (B). In B the fully (lower) and partially (upper) endo H-sensitive forms of the protein are shown.

Effects of N-Linked Glycosylation Site Mutations on Receptor Processing by the Golgi Apparatus-- Prior to processing in the Golgi apparatus, newly synthesized mSR-BI in the ER contains the high mannose forms of N-linked oligosaccharides that are all sensitive to cleavage by the enzyme endoglycosidase H (endo H (33)). After modification in the Golgi apparatus, the processed form of mSR-BI, when expressed in either stably transfected CHO cells in culture or adrenal glands in vivo, contains two classes of N-linked oligosaccharides: endo H-resistant chains (complex type N-linked sugars) and endo H-sensitive chains (either high mannose or hybrid type N-linked sugars) (33). The extent of processing (degree of endo H resistance of the processed receptor) varies depending on the cells/tissue (33). Fig. 1B shows the effects of endo H treatment of cell lysates on the electrophoretic mobilities of wild-type mSR-BI (lane 1) or the single Asn right-arrow Gln glycosylation mutants (lanes 2-12) expressed transiently in COS cells. As was previously observed in CHO cells, two immunoreactive bands were observed for the endo H-digested wild-type receptor in COS cells (lane 1). The lower band is the fully endo H-sensitive form of the receptor and presumably represents the precursor form of the protein prior to Golgi processing (33-35). The upper band represents a processed, partially endo H-resistant form. Most of the N-linked oligosaccharides in COS cells were endo H-sensitive after Golgi processing, the mobility of the processed, partially endo H-resistant form was only slightly less than that of the fully endo H-sensitive form and significantly greater than that of the receptor not subjected to endo H digestion (Fig. 1A, lanes 5, 10, and 12).

The doublet patterns of precursor and processed forms after endo H treatment were similar to that of the wild-type receptor for seven of the mutants: 383, 330, 310, 288, 227, and 102 (Fig. 1B, lanes 2-7 and 12). The relative ratios of the intensities of the upper and lower bands varied, raising the possibility that processing rates or stabilities of the mutants might have differed from those of the wild-type in some cases. Although these results are consistent with all of these seven sites in the wild-type receptor normally carrying endo H-sensitive chains, alternative explanations are possible (e.g. loss of one glycosylation site might alter the processing at another site). Indeed, the reproducibly lower mobility of the processed bands in the 212 and 116 mutants (lanes 8 and 10) is most likely due to a change in the structure of one or more oligosaccharides at one or more other sites (e.g. additional endo H-resistant chains or altered structure of the endo H-resistant chains). The most striking abnormalities in the doublet patterns were seen for the 173 and 108 mutants, where very little (108, lane 11) or no (173, lane 9) processed forms were detected. Although it is possible that all of the N-linked sugars on these two mutants remain endo H-sensitive after passing through the Golgi, an alternative possibility is that these mutations might have interfered with exit of the receptors from the ER, substantially reducing Golgi-mediated processing and cell surface expression.

Effects of N-Linked Glycosylation Site Mutations on Cell Surface Expression-- To address this later possibility, we used a rabbit polyclonal antibody (KKB-1) that recognizes apparently glycosylation independent (see "Experimental Procedures") epitopes in the extracellular domain of mSR-BI to measure cell surface expression of the wild-type mSR-BI and the mutants by transiently transfected COS cells. Transfected cells were incubated with KKB-1, washed, and incubated with an FITC-labeled anti-rabbit IgG secondary antibody, and then cellular fluorescence was quantitated by flow cytometry as previously described (6, 7, 9, 25). Fig. 2A shows that mutations at positions 108 and 173 substantially reduced cell surface immunodetectable mSR-BI, whereas the other single glycosylation mutations had little effect on surface expression relative to that of the wild-type mSR-BI ("SR-BI"). These experiments suggest that the N-linked oligosaccharide chains at positions 108 and 173, but not the others, are critical determinants of cell surface expression. It was possible that the conversion of the Asn side chains themselves at positions 108 or 173, rather than the loss of N-glycosylation, was responsible for the reduced processing and surface expression of these mutants. Therefore, a different class of mutation, Thr right-arrow Ala, in the consensus glycosylation sequence (Asn-X-Thr) that would prevent N-glycosylation was introduced at these sites. Fig. 3A shows that surface expression was even lower in the Thr right-arrow Ala mutants than the Asn right-arrow Gln mutants (reduction relative to wild-type control: 173, 92% versus 58%; 108, 84% versus 67%). Thus, glycosylation at positions 173 and 108 appear to be required for normal mSR-BI expression on the surface of COS cells.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of N-glycosylation site mutations (Asn right-arrow Gln) of mSR-BI on cell surface expression, 125I-HDL binding, and lipid uptake from DiI-HDL. On day 0, 1.5 × 105 COS M6 cells were plated in 24-well dishes in medium B. On day 1, cells were transfected with wild-type or mutant SR-BI encoding and "empty vector" control plasmid cDNAs using the DEAE-dextran method. On day 3 the cells were analyzed as described under "Experimental Procedures." A, cell surface receptor-specific expression was determined by flow cytometry using an anti-SR-BI polyclonal antibody (KKB-1) and an FITC-labeled secondary antibody. B and C, receptor-specific HDL binding activity was determined after a 1.5-h incubation with 125I-HDL (10 µg of protein/ml). D and E, receptor-specific lipid uptake activity was determined by flow cytometry after a 2-h incubation with DiI-HDL (10 µg of protein/ml). In all cases, the receptor-specific values were calculated as the differences between the determinations from cells transfected by the wild-type or mutant mSR-BI cDNAs and those from the cells transfected with the empty vector control. In some experiments, incubations with DiI-HDL were immediately followed by incubations with the antibodies to permit simultaneous determination of lipid uptake and surface expression by two-color flow cytometry. In A, B, and D, the 100% of control values are those of the wild-type mSR-BI measured in the same assay. The measured values for A and D were fluorescence intensities in arbitrary units. Typically, the fluorescence intensities for control cells transfected with an empty vector were 2-3% (surface expression) and 5-10% (DiI uptake) of those of cells expressing wild-type mSR-BI. In B, the 100% of control binding values were typically ~100 ng of 125I-HDL protein/mg of cell protein with empty vector control binding values of ~1-10%. The surface expression-corrected values for binding and lipid uptake in C and E, respectively, were calculated by dividing the percentage of control value for each of these parameters by the corresponding value for surface expression measured in the same experiment. All of the values shown represent the means from at least four and as many as nine independent transfections and are from multiple independent experiments. Each error bar represents the standard error of the mean.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Comparison of the effects of Asn right-arrow Gln and Thr right-arrow Ala N-glycosylation site mutations at positions 108 and 173 of mSR-BI on cell surface expression and lipid uptake from DiI-HDL. COS M6 cells were transiently transfected with expression vectors encoding wild-type mSR-BI or mSR-BI with either Asn right-arrow Gln or Thr right-arrow Ala mutations in the N-glycosylation sites at positions 108 and 173, and cell surface expression (A, KKB-1 antibody binding) and DiI-uptake from DiI-HDL (B and C) were simultaneously measured by flow cytometry as described in the legend to Fig. 2. The receptor-specific values were calculated as the means of the differences between the determinations from cells transfected by the wild-type or mutant mSR-BI cDNAs and those from the cells transfected with the empty vector control and are expressed as the percentage of the wild-type mSR-BI value. The surface expression-corrected values for lipid uptake in C were calculated by dividing the percentage of control value for each of these parameters by the corresponding value for percentage of surface expression.

Effects of N-Linked Glycosylation Site Mutations on Receptor Activity-- Two characteristic activities of SR-BI are its abilities to bind HDL and to transfer lipids such as cholesteryl esters or the hydrophobic fluorescent dye DiI from HDL to cells. These activities in transiently transfected COS cells were measured using 125I-HDL (10 µg of protein/ml, lipoprotein binding activity) and DiI-labeled HDL (DiI-HDL, 10 µg of protein/ml, lipid transfer activity) as described under "Experimental Procedures." Fig. 2B shows that the absolute levels of 125I-HDL binding to COS cells expressing all but two of the mutants were similar to that of the cells expressing the wild-type receptor. The exceptions were the 173 and 108 mutants that exhibited substantially lower binding. The result is consistent with the finding that there was substantially lower surface expression of these mutant receptors (Fig. 2A). When the binding data were corrected to normalize for the extent of surface expression (Fig. 2C), there were no statistically significant differences among the mutant and wild-type receptors, including the 173 and 108 mutants. This suggests that the mutations at positions 173 and 108 did not interfere with the capacity to bind HDL of those relatively few mutant receptor proteins that were able to be transported to the cell surface. Virtually identical results were obtained when quantitative binding of fluorescently labeled Alexa-HDL (6) was measured using flow cytometry (data not shown).

There was greater mutant-to-mutant variation in DiI uptake than in 125I-HDL binding (Fig. 2D). Relative to the wild-type receptor, small, but reproducible, reductions in receptor-mediated lipid uptake were exhibited by the 310, 255, and 212 mutants, even after correction for surface expression (Fig. 2, D and E). As expected, there was dramatically less DiI uptake by the cells expressing 173 and 108 mutants than those expressing the wild-type receptor (Fig. 2D). These substantially reduced levels of lipid uptake were striking even after correction for surface expression (Fig. 2E). This suggested that, unlike the apparently normal binding activities, the lipid transport activities of these two mutants were significantly reduced relative to wild-type controls. Almost identical results for cell surface expression corrected DiI uptake were observed using the Thr right-arrow Ala mutations at positions 173 and 108 in place of the Asn right-arrow Gln mutations (Fig. 3, B and C).

The low level of expression of the 173 and 108 mutants made it difficult to characterize further the properties of these mutants in transiently transfected COS cells. For example, we wanted to determine if these mutations affected the uptake of cholesteryl ether from HDL in a fashion similar to that for DiI uptake. We therefore attempted to generate stable cell lines expressing higher cell surface levels of these mutants by transfection of ldlA-7 cells and selection of cells with high surface expression using the KKB-1 antibody and flow cytometry. The ldlA-7 cells are LDL-receptor-deficient mutants that were isolated from mutagen-treated Chinese hamster ovary cells (32). We were unsuccessful in isolating transfectants expressing high levels of the 108 mutant but did succeed with the 173 mutant.

Fig. 4A shows the concentration dependence of 125I-HDL binding to untransfected control cells (ldlA-7, crosses), and stably transfected cells expressing the wild-type receptor (ldlA[mSR-BI] (1), open circles) or the 173 mutant (ldlA[N173Q], filled circles). Although the absolute amount of binding of 125I-HDL to ldlA[N173Q] cells was lower than that to ldlA[mSR-BI] cells, it was significantly higher than that of the control ldlA-7 cells. When the transfected receptor-specific binding data (calculated as the difference between binding to transfected and untransfected cells) were corrected by normalizing for the level of receptor surface expression, the extents of binding to the wild-type receptor and the 173 mutant were similar and there was apparently no difference in the binding affinities (Fig. 4C). Thus, the results for cell surface expression-corrected 125I-HDL binding in stably transfected ldlA-7 cells were similar to those in the transiently transfected COS cells.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Concentration dependence of 125I-HDL binding (A and B) and [3H]cholesteryl oleyl ether ([3H]CEt) uptake from [3H]CEt-HDL (C and D) by ldlA-7, ldlA[mSR-BI], and ldlA[N173Q] cells. Stable transfectants expressing either wild-type mSR-BI (ldlA[mSR-BI], open circles), mSR-BI with an N-glycosylation site mutation at position 173 (ldlA[N173Q], filled circles), or untransfected control cells (ldlA-7, "x") were plated on day 0 and assayed on day 2 for 125I-HDL binding or [3H]CEt uptake from [3H]CEt-HDL. Incubations with the labeled lipoproteins (10 µg of protein/ml) in the absence (duplicate incubations) or presence (single incubations) of a 40-fold excess of unlabeled HDL were performed at 37 °C for 1.5 h. The amounts of specific binding or uptake in A and C were determined as the differences between measurements made in the absence or presence of unlabeled HDL. The transfected receptor-specific corrected values in B and D were calculated by subtracting the values of the untransfected cells from those of the transfected cells and then multiplying the values for the ldlA[N173Q] cells by 3.29 to correct for the lower surface expression of the mutant receptor relative to that of the wild-type receptor in the transfected cells. The error bars represent the range of values for duplicate determinations.

Fig. 4B shows the concentration dependence of the cellular uptake of 3H-labeled cholesteryl ether ([3H]CEt) from HDL ([3H]CEt-HDL). The nonhydrolyzable cholesteryl ether was used rather than cholesteryl ester to simplify the analysis by preventing intracellular hydrolysis. There was robust selective uptake of the [3H]CEt from [3H]CEt-HDL by the ldlA[mSR-BI] cells, but uptake by ldlA[N173Q] cells was almost the same as that by the untransfected controls. After correction for the differences in surface expression, it is clear that the cholesteryl ether uptake mediated by the 173 mutant was substantially less efficient than that by the wild-type receptor. As additional controls, we isolated stable transfectants of ldlA-7 cells expressing the 102, 116, 212, 227, 255, 288, 310, and 330 mutants and observed (data not shown) that the results for surface expression, 125I-HDL binding, and lipid uptake ([3H]CEt uptake from [3H]CEt-HDL) were all similar to those obtained with the COS cells (Fig. 2).

The lower surface expression of the 173 mutant relative to that of wild-type mSR-BI raised the possibility that the reduced lipid uptake mediated by this mutant may have been a consequence of its reduced surface expression rather than of its altered intrinsic activity. This might arise if the expression level (concentration of receptors on the cell surface) can influence lipid transport activity. For example, this might occur if cell surface concentration-dependent oligomerization of receptor proteins were important for lipid transfer activity. This issue was addressed by analysis of the ldlA[mSR-BI] and ldlA[N173Q] cells using two-color flow cytometry that simultaneously measured on individual cells both surface expression of mSR-BI (binding of the KKB-1 antibody) and lipid uptake (DiI accumulation during a 2-h incubation with DiI-HDL at 37 °C). Fig. 5 shows flow cytograms in which the extent of KKB-1 binding, detected with a fluorescent secondary antibody, is shown on the horizontal axis and cellular DiI fluorescence (lipid uptake) is presented on the vertical axis. The arrows in panels A (ldlA[mSR-BI]) and B (ldlA[N173Q]) represent the surface expression to lipid uptake distribution observed in the ldlA[mSR-BI] cells (panel A). At every level of receptor surface expression above the untransfected cell background, lipid uptake was greater for the cells expressing the wild-type receptor than those expressing the 173 mutant (i.e. the distribution in panel B falls below the arrow). The boxes in panels A and B define sets of cells that exhibit almost identical average levels of surface expression (114 and 112 arbitrary units/cell, panel C). Despite similar levels of surface receptors, there was substantially greater uptake of DiI by the ldlA[mSR-BI] cells (panel C). Thus, differing mean levels of surface expression do not account for the differences in the efficiency of DiI uptake from DiI-HDL mediated by wild-type mSR-BI and the 173 mutant. Furthermore, immunofluorescence analysis of cells using the KKB-1 antibody did not show any gross differences in the surface distributions of the receptors on ldlA[mSR-BI] and ldlA[N173Q] cells (Fig. 6). Thus, in addition to reducing the level of cell surface expression of the receptor, the mutation at position 173 substantially reduced the intrinsic ability of the receptor to mediate selective uptake without reducing its intrinsic ability to bind HDL.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Two-color fluorescence flow cytometric analysis of receptor cell surface expression (horizontal axes) and DiI uptake from DiI-HDL (vertical axes) by ldlA[mSR-BI] and ldlA[N173Q] cells. On day 0, ldlA[mSR-BI] and ldlA[N173Q] cells were plated in 24-well dishes (150,000 cells/well). On day 2, cell surface expression of the receptors determined using the KKB-1 antibody and uptake of DiI from DiI-HDL (10 µg of protein/ml, 2 h at 37 °C) were measured using flow cytometry as described under "Experimental Procedures." For each cell, the relative fluorescence intensity for FITC fluorescence (secondary antibody for surface expression, horizontal axes) and DiI (lipid uptake, vertical axes) is indicated by a red dot on the graph (log scales). The mean values for surface expression and DiI uptake (and their ratios) are shown in C.


View larger version (117K):
[in this window]
[in a new window]
 
Fig. 6.   Immunofluorescence localization of wild-type and the N173Q glycosylation site mutant mSR-BI in ldlA[mSR-BI] and ldlA[N173Q] cells. On day O, ldlA[mSR-BI] (A) or ldlA[N173Q] (B) cells (150,000 cells/well, medium B) were plated onto coverslips in 6-cm dishes. On day 2, cells were fixed with 4% formaldehyde in PBS and washed, and the distribution of the receptors was detected by immunofluorescence using the anti-SR-BI antibody KKB-1 (1:1000) as described under "Experimental Procedures." Bar = 50 µm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The HDL receptor SR-BI has been shown to mediate physiologically relevant selective lipid uptake and, as a consequence, play an important role in lipoprotein-mediated cholesterol transport (2). Previous studies have established that the mature form of SR-BI has multiple (at least five) N-linked oligosaccharides, some of which are endo H-resistant (complex structure) and some of which are endo H-sensitive (high mannose or hybrid structures) (33). In the current study we used site-directed mutagenesis of each potential N-linked glycosylation site (extracellular Asn-X (not Pro)-Ser/Thr) on murine SR-BI and transient expression in COS cells to determine which sites were glycosylated and which, if any, of the glycosylation sites were required for cell surface expression and receptor function.

At each of the 11 potential N-linked sites, mutation of the essential Asn to Gln increased the electrophoretic mobility of the receptor, indicating that all 11 sites in the wild-type mSR-BI are N-glycosylated. In the two cases examined (positions 108 and 173) Ser/Thr to Ala mutations had the same effect. These findings are consistent with previous partial and exhaustive N-glycanase hydrolysis experiments that showed that there are at least five N-linked sugars on mSR-BI stably expressed in ldlA[mSR-BI] cells (33). Another similarity between this study using transiently transfected COS cells and earlier reports with stably transfected ldlA[mSR-BI] cells is our finding of partial sensitivity of the mature form of the receptor to endoglycosidase H. The extent of processing of the N-linked chains to complex types appeared to be lower in the COS cells than in ldlA[mSR-BI] cells, because the electrophoretic mobility of the endoglycosidase H-treated mature receptors was greater (lower apparent mass) in the COS cells compared with the ldlA[mSR-BI] cells. The most dramatic effect of these mutations was the reduction of cell surface expression of the receptors with mutations at positions 108 and 173.

SR-BI is a member of the CD36 superfamily of proteins that includes the mammalian proteins CD36 (36, 37) and LIMPII (a lysosomal integral membrane protein (38)), two Drosophila melanogaster proteins, emp (39) and croquemort (a hemocyte/macrophage receptor) (40, 41), SnmP-1 (a silk moth olfatory neuron membrane protein) (42), and one putative Caenorhabditis elegans protein (GenBankTM Z54270). Table I shows the degree of conservation of the 11 N-linked Asn-X (not Pro)-Ser/Thr sites in the 22 sequences of these proteins, identified using Psi-blast (43). The least well-conserved sites are at positions 288 (only in 1/22 sequences, murine SR-BI) and 116 (only in murine and rat SR-BI). Thus, it was not surprising that there were no effects on the activities of mSR-BI by mutating these sites. The most highly conserved potential glycosylation site based on ClustalW alignment (44) is at position 212. This site is present in all 22 sequences of CD36 superfamily members from species as diverse as humans, moths, and fruit flies. However, mutating this site resulted in only a small reduction in SR-BI surface expression and virtually no loss of intrinsic receptor activity. In contrast, the functionally important site at position 173, although conserved in all mammalian SR-BI sequences (6/6), was only present in one of the other 16 sequences (rat CD36). This raises the possibility that this site might play a distinctive role in determining the folding, stability, and/or activity of SR-BI. However, it should be noted that, although the site at position 383 is present in all six mammalian SR-BI sequences and not in any other superfamily members, mutation of site 383 had no deleterious effects on the surface expression or activities of mSR-BI.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Potential N-linked glycosylation sites in members of the CD36 superfamily of proteins
SR-BI, murine, rat, hamster, bovine, porcine, human; CD36, murine, rat, hamster, bovine, rabbit, human; LIMPII, murine, rat, human; SNMP-1, bombyx, heliothis, manduca, moth; Dros. M., Drosophila melanogaster; EMP, croquemort; C. elegans, EST, GenBank Z54270. Alignment was performed using ClustalW (available at dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html) (44).

As has been shown for other N-glycosylated proteins, it is likely that glycosylation of positions 108 and 173 in mSR-BI was important for folding in the ER and consequent transport to and through the Golgi, where the protein develops partial endo H resistance, and then to the cell surface (45). Glycosylation of these sites may also have affected the stability of the receptor. The relatively few molecules of the 108 and 173 mutants that were expressed on the cell surface could bind 125I-HDL at least as well as wild-type receptors, but were very inefficient at mediating cellular uptake of lipids (DiI, [3H]CEt) from HDL. Thus, the activities of these mutants are similar to those of the SR-BI homolog CD36, except CD36 is expressed at high levels on the surfaces of cells, such as transiently transfected COS cells (6, 22). Construction and characterization of SR-BI/CD36 chimeras established that differences in the extracellular loops of these two receptors, wherein the 108 and 173 sites reside, were responsible for the differences in their abilities to efficiently transport lipids (6, 22, 26). Indeed, although all six known SR-BI sequences have the potential glycosylation sites at positions 108 and 173, none of the six CD36 sequences have the site at 108 and only one has the site at position 173. Thus, it is possible that the oligosaccharides at these positions may not only be important for folding and export from the ER, they may contribute to the lipid transport process either by indirectly leading to the formation of key conformations (or conformational changes) of the receptor or perhaps by directly participating in the lipid transport process.

We detected using immunofluorescence no gross differences in the surface distributions of the wild-type and N173Q receptors expressed in stably transfected cells. Although this suggests that the relative amounts of receptor clustering in membrane microdomains, including caveolae (33), may not have been influenced by the altered glycosylation at this site, further ultrastructural and/or biochemical analyses will be required to determine if any glycosylation-dependent shifts in the distribution of the receptors might have influenced their lipid transport activity. Recent examination of the activity of essentially homogeneously pure mSR-BI reconstituted into phosphatidylcholine/cholesterol liposomes has shown that SR-BI-mediated HDL binding and selective lipid uptake are intrinsic properties of the receptor that do not require the intervention of other proteins or specific cellular structures or compartments (24). However, the effects on the glycosylation-dependent selective lipid uptake activity of differing membrane lipid compositions by mSR-BI, such as those of caveolae and the bulk plasma membrane, remain to be explored.

Additional studies will be required to determine precisely how mutations at sites 108 and 173 reduced the surface expression and lipid transport activity of mSR-BI without substantially altering its ability to bind HDL. The ability to uncouple the HDL binding and lipid transport activities of mSR-BI by in vitro mutagenesis should provide a powerful tool for further analysis of the mechanism underlying SR-BI-mediated selective lipid uptake.

    ACKNOWLEDGEMENTS

We thank Xiang-ju Gu and Marsha Penman for advice and assistance, G. Paradis and M. Jennings for assistance with flow cytometry, and Karen Kozarsky for generously providing the KKB-1 antibody.

    FOOTNOTES

* This work was supported in part by Grant HL52212 from NHLBI, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger MIT-Generalitat de Catalunya and Spanish Ministry of Science and Technology Postdoctoral Fellow. Current address: Unitat de Farmacologia, Facultat de Farmacia, Universitat de Barcelona, Nucli Universitari de Pedralbes, Barcelona 08028, Spain.

§ To whom correspondence should be addressed: Dept. of Biology, Massachusetts Institute of Technology, Rm. 68-483, Cambridge, MA 02139. Tel.: 617-253-6793; Fax: 617-258-5851; E-mail: krieger@mit.edu.

Published, JBC Papers in Press, November 11, 2002, DOI 10.1074/jbc.M211073200

    ABBREVIATIONS

The abbreviations used are: SR-BI, scavenger receptor class B type I; HDL, high density lipoprotein; LDL, low density lipoprotein; CEt, cholesteryl oleoyl ether; DiI, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; PBS, phosphate-buffered saline; fPBS, Ca2+- and Mg2+-free PBS; endo H, endoglycosidase H; FITC, fluorescein isothiocyanate; BSA, bovine serum albumin; CHO, Chinese hamster ovary; CMV, cytomegalovirus; ER, endoplasmic reticulum.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520[Abstract]
2. Krieger, M. (1999) Ann. Rev. Biochem. 68, 523-588[CrossRef][Medline] [Order article via Infotrieve]
3. Brown, M. S., and Goldstein, J. L. (1986) Science 232, 34-47[Medline] [Order article via Infotrieve]
4. Glass, C., Pittman, R. C., Weinstein, D. B., and Steinberg, D. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 5435-5439[Abstract]
5. Stein, Y., Dabach, Y., Hollander, G., Halperin, G., and Stein, O. (1983) Biochim. Biophys. Acta 752, 98-105[Medline] [Order article via Infotrieve]
6. Gu, X., Trigatti, B., Xu, S., Acton, S., Babitt, J., and Krieger, M. (1998) J. Biol. Chem. 273, 26338-26348[Abstract/Free Full Text]
7. Liu, T., Krieger, M., Kan, H. Y., and Zannis, V. I. (2002) J. Biol. Chem. 277, 21576-21584[Abstract/Free Full Text]
8. Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M. L., Phillips, M. C., Rothblat, G. H., Swaney, J. B., and Tall, A. R. (1997) J. Biol. Chem. 272, 20982-20985[Abstract/Free Full Text]
9. Gu, X., Kozarsky, K., and Krieger, M. (2000) J. Biol. Chem. 275, 29993-30001[Abstract/Free Full Text]
10. de la Llera-Moya, M., Rothblat, G. H., Connelly, M. A., Kellner-Weibel, G., Sakr, S. W., Phillips, M. C., and Williams, D. L. (1999) J. Lipid Res. 40, 575-580[Abstract/Free Full Text]
11. Rigotti, A., Trigatti, B. L., Penman, M., Rayburn, H., Herz, J., and Krieger, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12610-12615[Abstract/Free Full Text]
12. Trigatti, B., Rayburn, H., Vinals, M., Braun, A., Miettinen, H., Penman, M., Hertz, M., Schrenzel, M., Amigo, L., Rigotti, A., and Krieger, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9322-9327[Abstract/Free Full Text]
13. Kozarsky, K. F., Donahee, M. H., Rigotti, A., Iqbal, S. N., Edelman, E. R., and Krieger, M. (1997) Nature 387, 414-417[CrossRef][Medline] [Order article via Infotrieve]
14. Ueda, Y., Gong, E., Royer, L., Cooper, P. N., Francone, O. L., and Rubin, E. M. (2000) J. Biol. Chem. 275, 20368-20373[Abstract/Free Full Text]
15. Ueda, Y., Royer, L., Gong, E., Zhang, J., Cooper, P., Francone, O., and Rubin, E. (1999) J. Biol. Chem. 274, 7165-7171[Abstract/Free Full Text]
16. Arai, T., Wang, N., Bezouevski, M., Welch, C., and Tall, A. R. (1999) J. Biol. Chem. 274, 2366-2371[Abstract/Free Full Text]
17. Wang, N., Arai, T., Rinninger, F., and Tall, A. R. (1998) J. Biol. Chem. 273, 32920-32926[Abstract/Free Full Text]
18. Kozarsky, K. F., Donahee, M. H., Glick, J. M., Krieger, M., and Rader, D. J. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 721-727[Abstract/Free Full Text]
19. Mardones, P., Quinones, V., Amigo, L., Moreno, M., Miquel, J. F., Schwarz, M., Miettinen, H. E., Trigatti, B. L., Krieger, M., VanPatten, S., Cohen, D. E., and Rigotti, A. (2001) J. Lipid Res. 42, 170-180[Abstract/Free Full Text]
20. Miettinen, H. E., Rayburn, H., and Krieger, M. (2001) J. Clin. Invest. 108, 1717-1722[Abstract/Free Full Text]
21. Holm, T. M., Braun, A., Trigatti, B. L., Brugnara, C., Sakamoto, M., Krieger, M., and Andrews, N. C. (2002) Blood 99, 1817-1824[Abstract/Free Full Text]
22. Connelly, M. A., Klein, S. M., Azhar, S., Abumrad, N. A., and Williams, D. L. (1999) J. Biol. Chem. 274, 41-47[Abstract/Free Full Text]
23. Braun, A., Trigatti, B. L., Post, M. J., Sato, K., Simons, M., Edelberg, J. M., Rosenberg, R. D., Schrenzel, M., and Krieger, M. (2002) Circ. Res. 90, 270-276[Abstract/Free Full Text]
24. Liu, B., and Krieger, M. (2002) J. Biol. Chem. 277, 34125-34135[Abstract/Free Full Text]
25. Gu, X., Lawrence, R., and Krieger, M. (2000) J. Biol. Chem. 275, 9120-9130[Abstract/Free Full Text]
26. Connelly, M. A., de la Llera-Moya, M., Monzo, P., Yancey, P. G., Drazul, D., Stoudt, G., Fournier, N., Klein, S. M., Rothblat, G. H., and Williams, D. L. (2001) Biochemistry 40, 5249-5259[Medline] [Order article via Infotrieve]
27. Helenius, A. (1994) Mol. Biol. Cell 5, 253-265[Medline] [Order article via Infotrieve]
28. Opdenakker, G., Rudd, P. M., Ponting, C. P., and Dwek, A. R. (1993) FASEB J. 7, 1330-1337[Abstract/Free Full Text]
29. Imperiali, B., and Rickert, K. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 97-101[Abstract]
30. Krieger, M. (1983) Cell 33, 413-422[CrossRef][Medline] [Order article via Infotrieve]
31. Acton, S. L., Scherer, P. E., Lodish, H. F., and Krieger, M. (1994) J. Biol. Chem. 269, 21003-21009[Abstract/Free Full Text]
32. Kingsley, D., and Krieger, M. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 5454-5458[Abstract]
33. Babbit, J., Trigatti, B. L., Rigotti, A., Smart, E. J., Anderson, R. G., Xu, S., and Krieger, M. (1997) J. Biol. Chem. 272, 13242-13249[Abstract/Free Full Text]
34. Ray, K., Fan, G. F., Goldsmith, P. K., and Spiegel, A. M. (1997) J. Biol. Chem. 272, 31355-31361[Abstract/Free Full Text]
35. Bai, M., Quinn, S., Trivedi, S., Kifor, O., Pearce, S. H., Pollak, M. R., Krapcho, K., Hebert, S. C., and Brown, E. M. (1996) J. Biol. Chem. 271, 19537-19545[Abstract/Free Full Text]
36. Calvo, D., Dopazo, J., and Vega, M. A. (1995) Genomics 25, 100-106[CrossRef][Medline] [Order article via Infotrieve]
37. Oquendo, P., Hundt, E., Lawler, J., and Seed, B. (1989) Cell 58, 95-101[Medline] [Order article via Infotrieve]
38. Vega, M. A., Segui-Real, B., Garcia, J. A., Cales, C., Rodriguez, F., Vanderkerckhove, J., and Sandoval, I. V. (1991) J. Biol. Chem. 266, 16818-16824[Abstract/Free Full Text]
39. Hart, K., and Wilcox, M. (1993) J. Mol. Biol. 234, 249-253[CrossRef][Medline] [Order article via Infotrieve]
40. Franc, N. C., Dimarcq, J. L., Lagueux, M., Hoffmann, J., and Ezekowitz, R. A. (1996) Immunity 4, 431-443[Medline] [Order article via Infotrieve]
41. Franc, N. C., Heitzler, P., Ezekowitz, R. A., and White, K. (1999) Science 284, 1991-1994[Abstract/Free Full Text]
42. Rogers, M. E., Sun, M., Lerner, M. R., and Vogt, R. G. (1997) J. Biol. Chem. 272, 14792-14799[Abstract/Free Full Text]
43. Altschul, S., Madden, T., Shaffer, A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. (1997) Nucleic Acids Res. 25, 3389-3402[Abstract/Free Full Text]
44. Thompson, J. D., Higgins, D., and Gibson, T. (1994) Nucleic Acids Res. 22, 4673-4680[Abstract]
45. Rose, J. K., and Doms, R. W. (1988) Annu. Rev. Biochem. 4, 257-288
46. Varban, M. L., Rinninger, F., Wang, N., Fairchild-Huntress, V., Dunmore, J., Fang, Q., Gosselin, M. L., Dixon, D. L., Deeds, J. D., Acton, S. L., Tall, A. R., and Huszar, D. (1998) Proc. Natl. Acad. Sci. U. S. A.  95, 4619-4624[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.